Premium
POSTNATAL ROSIGLITAZONE ADMINISTRATION TO NEONATAL RAT PUPS DOES NOT ALTER THE ADULT METABOLIC PHENOTYPE
Author(s) -
Rehan Virender K.,
Truong Nghia,
Sakurai Reiko,
Lee WaiNang Paul,
Torday John S.
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.893.5
Subject(s) - rosiglitazone , endocrinology , medicine , triglyceride , insulin , insulin resistance , biology , cholesterol
We have previously shown that systemically administered Rosiglitazone (RGZ), a PPARγ agonist, up to 7 days of life significantly enhances lung maturation without affecting serum electrolytes, blood glucose, blood gases and serum lipid profile in the newborn period. However, whether this intervention in early neonatal life alters the adult metabolic phenotype is not known. Newborn Sprague Dawley rats were given either saline or RGZ (0.3 – 3 mg/kg BW) i.p. from postnatal day 1 to 7. Pups were allowed to breast feed ad lib and then weaned to rat chow on postnatal day 21. Following standard methods, glucose and insulin tolerance tests were performed at 14 wks of age. To assess the effects of early RGZ administration on glucose and fatty acid synthesis, deuterium labeling studies were performed. Animals were sacrificed, following which serum and tissues (skeletal muscle, liver, lung, brown and white fat) were collected for the expression of adipogenic differentiaton markers by Western blotting. There was no effect of early postnatal RGZ administration on BW, glucose or insulin tolerance, serum cholesterol and triglyceride levels, or triglyceride and fatty acid synthesis in both males and females. Treatment with the PPARγ agonist RGZ in early neonatal life does not alter developmental metabolic programming, and does not lead to an altered metabolic phenotype in the adult. Grant Support: NIH (HL75405, HD51857, HD058948).